Claims

1. The use of a mussel adhesive protein ("MAP") as an active ingredient in the manufacture of a composition for the treatment of inflammation of the mucosa selected from oral mucositis, rhinitis, pharyngitis, laryngitis and tracheitis, wherein the MAP comprises one or more of the sub-types selected from the group mytilus edilus foot protein ("mefp")-1, mefp-2, mefp-3, mefp-4, mefp-5 and mefp-6.

2. The use according to claim 1, wherein the MAP comprises mefp-1.

3. The use according to any one of claims 1-2, wherein the MAP concentration is 0.1-15.0 mg/mL.

4. The use according to any one of claims 1-3, wherein the composition is a liquid formulation, a gel formulation or a foam formulation.

5. The use according to any one of claims 1-4, wherein MAP in the final product is in a range of pH 1.0-7.0, and in particular, in a range of pH 3.0-6.5.

6. The use according to any one of claims 1-5, wherein the composition is to be used by means of oral administration, sublingual administration, a nasal spray and an oral spray.

7. The use of MAP according to any one of claims 1-6 wherein the composition is a medicament, a disinfecting product or a healthcare product.